导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 12.05% | 742/4773 |
| 近一周 | 0.26% | 692/5465 |
| 近一月 | -6.16% | 4065/5421 |
| 近一季 | -11.12% | 3869/5231 |
| 近半年 | 11.82% | 508/4920 |
| 近一年 | 15.88% | 760/4394 |
| 近两年 | 162.46% | 177/2954 |
| 近三年 | 118.29% | 105/2253 |
| 成立以来 | 40.56% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.11% 4036/4961 |
51.40% 569/5312 |
- - |
- - |
| 2025 | 63.71% 165/4813 |
5.07% 835/3635 |
1.23% 2412/4076 |
54.65% 209/4524 |
-0.48% 2508/4813 |
| 2024 | 20.18% 484/3463 |
-1.39% 1220/2808 |
-2.82% 1257/3014 |
14.40% 1980/3129 |
9.63% 316/3463 |
| 2023 | 10.94% 83/2656 |
36.31% 50/2280 |
-2.90% 706/2385 |
-13.52% 2154/2515 |
-3.07% 595/2655 |
| 2022 | -33.01% 1694/2207 |
-19.54% 1470/1919 |
-3.26% 1806/2016 |
-19.60% 1793/2113 |
7.05% 331/2208 |
| 2021 | 8.83% 470/1822 |
-6.15% 981/1255 |
13.58% 284/1330 |
-7.67% 1075/1466 |
10.59% 100/1822 |
| 2020 | - - |
- - |
- - |
-10.93% 1134/1164 |
-0.29% 1069/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华夏中证人工智能主题ETF联接A VS. 长安沪深300非周期A(740101) |